Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.

The following treatment-related factors that remained independent predictors for OS in multivariate analysis were as follows: AZA first-line treatment, hematologic improvement, and further deepening of response after first response; best marrow response ( p = 0.642) did not meet the 0.05 significance level for inclusion in the multivariate analysis; azacitidine pause due to adverse events was associated with longer OS in multivariate analysis; dose reduction due to adverse events ( p = 0.051) and fatigue limiting self-care ( p = 0.053) were borderline significant in multivariate analysis (Figs. 2 and 3 , and Supplemental Table 5 ).

also in 11,409 other papers